Bempikibart (ADX-914)
Alopecia Areata (AA)
Phase 2Active; Currently in SIGNAL-AA Phase 2a clinical trial; FDA Fast Track Designation granted.
Key Facts
Indication
Alopecia Areata (AA)
Phase
Phase 2
Status
Active; Currently in SIGNAL-AA Phase 2a clinical trial; FDA Fast Track Designation granted.
Company
About Q32 Bio
Q32 Bio is focused on discovering and developing innovative therapies that restore immune homeostasis in severe autoimmune and inflammatory diseases. The company's most advanced program, bempikibart, has shown promising clinical activity and a favorable safety profile in a Phase 2a trial for alopecia areata. Led by an experienced team of industry veterans, Q32 Bio is advancing a pipeline centered on modulating both the adaptive (via IL-7/TSLP) and innate (via complement) immune systems, with strategic evaluation ongoing for its complement platform.
View full company profile